Veracyte, Inc.
A maker of genomic tests that help doctors decide how to treat cancer, Veracyte reads a patient's tumor biology to answer questions like whether a thyroid nodule is benign or a prostate cancer needs aggressive treatment. Its best-known products are the Afirma thyroid test and the Decipher prostate test. Founded in 2006 as Calderome and renamed in 2008, the company's name blends the Latin for "truth" with the Greek suffix for "cell" — a nod to revealing what a patient's cells actually say.
Sold 1.55M
Granted 835.0K · Bought 60.0K · Sold 257.2K
Granted 1.32M · Bought 10.0K · Sold 936.0K
Granted 328.4K · Sold 65.0K
Granted 255.8K · Sold 33.7K
Granted 260.7K · Sold 62.9K
Granted 187.0K · Sold 49.6K
Granted 302.0K · Sold 147.0K
Granted 56.5K
Granted 213.9K · Sold 201.7K
Granted 63.2K · Sold 13.9K
Granted 481.3K · Sold 379.4K
Granted 114.2K · Sold 56.5K
Granted 56.5K
Granted 62.0K · Sold 17.4K
Granted 44.2K
Granted 92.1K · Sold 40.9K
Granted 158.0K · Sold 585.7K
Granted 53.1K · Sold 20.0K
Granted 59.2K · Bought 2.0K · Sold 28.7K
Granted 31.1K
Granted 31.1K
Granted 402.2K · Sold 367.5K
Granted 141.7K · Sold 139.8K
Granted 5.5K
Granted 50.0K · Sold 40.0K
Granted 43.7K · Sold 35.0K
Granted 7.5K
Granted 1.0K · Bought 3.1K
Granted 3.3K · Sold 3.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Atwood Brian GDirector, 10% owner · 2 transactions | — | 3.62Mas of Nov 2013 | — | — | — |
| Colella Samuel DDirector, 10% owner · 2 transactions | — | 3.62Mas of Nov 2013 | — | — | — |
| Versant Side Fund III, L.P. +2 co-filers10% owner · 2 transactions | — | 3.62Mas of Nov 2013 | — | — | — |
| Bonderman David +2 co-filers10% owner · 1 transaction | — | 3.55Mas of Nov 2013 | — | — | — |
| Byers Brook HDirector, 10% owner · 1 transaction | — | 3.55Mas of Nov 2013 | — | — | — |
| Blair James C10% owner · 2 transactions | — | 3.09Mas of Nov 2013 | — | — | — |
| Dovey Brian H10% owner · 2 transactions | — | 3.09Mas of Nov 2013 | — | — | — |
| Halak Brian K10% owner · 2 transactions | — | 3.09Mas of Nov 2013 | — | — | — |
| Schoemaker Kathleen K10% owner · 2 transactions | — | 3.09Mas of Nov 2013 | — | — | — |
| Vitullo Nicole10% owner · 2 transactions | — | 3.09Mas of Nov 2013 | — | — | — |
| Domain Partners VIII, L.P.10% owner · 1 transaction | — | 3.06Mas of Nov 2013 | — | — | — |
| Kleiner Perkins Caufield & Byers XII, LLC +2 co-filers10% owner · 2 transactions | — | 2.80Mas of Mar 2017 | — | — | — |
| Blair James C +6 co-filers10% owner, Director, 10% owner · 1 transaction | — | 2.76Mas of Sep 2014 | — | — | — |
| Treu Jesse IDirector · 18 transactions | — | 1.23Mas of Mar 2019 | — | — | 1.55M |
| Stapley MarcChief Executive Officer, Director · 42 transactions | — | 440.5K | 835.0K | 60.0K | 257.2K |
| Anderson Bonnie HDirector · 185 transactions | — | 176.2Kas of Jun 2023 | 1.32M | 10.0K | 936.0K |
| Chambers RebeccaChief Financial Officer · 40 transactions | — | 173.3K | 328.4K | — | 65.0K |
| Febbo Phillip G.Chief Scientific & Med Officer · 21 transactions | — | 149.8K | 255.8K | — | 33.7K |
| McGuire AnnieEVP, General Counsel · 40 transactions | — | 139.0K | 260.7K | — | 62.9K |
| Leite JohnGlobal Chief Commercial Off · 31 transactions | — | 132.3K | 187.0K | — | 49.6K |
| Kennedy KeithCOO / CFO · 42 transactions | — | 116.9Kas of Mar 2021 | 302.0K | — | 147.0K |
| Nova Tina SusanPresident, CLIA U.S. · 2 transactions | — | 77.0Kas of Mar 2022 | 56.5K | — | — |
| Hanna John Walter JRChief Commercial Officer · 50 transactions | — | 73.8Kas of Dec 2020 | 213.9K | — | 201.7K |
| Ho MarkPrincipal Accounting Officer · 13 transactions | — | 71.7Kas of Mar 2021 | 63.2K | — | 13.9K |
| Kennedy Giulia CChief Scientific & Med Officer · 139 transactions | — | 66.0Kas of Dec 2022 | 481.3K | — | 379.4K |
| Epstein Robert SDirector · 16 transactions | — | 57.7K | 114.2K | — | 56.5K |
| Barr EliavDirector · 5 transactions | — | 56.5K | 56.5K | — | — |
| Bhanji MunaDirector · 12 transactions | — | 44.6K | 62.0K | — | 17.4K |
| Haas Kevin RichardChief Dev and Tech Officer · 1 transaction | — | 44.2K | 44.2K | — | — |
| Wygant JonathanVP, Chief Accounting Officer · 26 transactions | — | 44.1K | 92.1K | — | 40.9K |
| Jones Evan/ FaDirector · 90 transactions | — | 34.6K | 158.0K | — | 585.7K |
| Bishop John LDirector · 7 transactions | — | 33.1Kas of Jul 2023 | 53.1K | — | 20.0K |
| Holstein JensDirector · 15 transactions | — | 32.5K | 59.2K | 2.0K | 28.7K |
| Miller Thomas F.Director · 3 transactions | — | 31.1K | 31.1K | — | — |
| Shafer David BrentDirector · 3 transactions | — | 31.1K | 31.1K | — | — |
| Hall Christopher MPresident and COO · 51 transactions | — | 28.3Kas of Jun 2019 | 402.2K | — | 367.5K |
| DP VIII Associates, L.P.10% owner · 1 transaction | — | 22.7Kas of Nov 2013 | — | — | — |
| Eastham KarinDirector · 46 transactions | — | 15.1K | 141.7K | — | 139.8K |
| Alley Beverly JaneVP, Corporate Controller · 1 transaction | — | 13.0Kas of May 2021 | 5.5K | — | — |
| Cohen Fred EDirector · 7 transactions | — | 10.0Kas of Oct 2020 | 50.0K | — | 40.0K |
| Gordon Kevin KDirector · 9 transactions | — | 8.7Kas of Jun 2022 | 43.7K | — | 35.0K |
| Erlinger III James HEVP, General Counsel · 1 transaction | — | 7.5Kas of Feb 2021 | 7.5K | — | — |
| Brooks JulieEVP, Gen Counsel and Secretary · 7 transactions | — | 4.2Kas of Jan 2017 | 1.0K | 3.1K | — |
| Guyer Shelly DChief Financial Officer · 6 transactions | — | 1.0Kas of Jul 2015 | 3.3K | — | 3.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -4.96M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.